OraSure Technologies, Inc. (NASDAQ:OSUR) Receives an Average Rating of “Hold” by Brokerages

0

Shares of OraSure Technologies, Inc. (NASDAQ:OSUR – Get Rating) have received a consensus rating of “Hold” from the six rating agencies that currently cover the company, Marketbeat.com reports. One research analyst rated the stock with a sell recommendation, two gave the company a hold recommendation and two gave the company a buy recommendation. The average 1-year target price among brokerages that have reported on the stock in the past year is $13.00.

A number of analysts have recently released reports on OSUR shares. Zacks Investment Research upgraded OraSure Technologies from a “sell” rating to a “hold” rating in a Tuesday, March 1, report. Lake Street Capital cut its target price on OraSure Technologies from $20.00 to $14.00 and set a “buy” rating on the stock in a research report on Thursday, January 6. TheStreet downgraded OraSure Technologies from a “c-” rating to a “d+” rating in a Friday, March 4 research report. Citigroup lowered its price target on OraSure Technologies from $15.00 to $12.00 and set a “buy” rating on the stock in a Thursday, February 24 report. Finally, StockNews.com downgraded OraSure Technologies from a “hold” rating to a “sell” rating in a report released Thursday.

NASDAQ OSUR shares opened at $6.49 on Friday. The company has a quick ratio of 3.46, a current ratio of 4.24 and a leverage ratio of 0.01. The stock has a fifty-day moving average price of $7.21 and a 200-day moving average price of $8.64. OraSure Technologies has a 1-year low of $6.45 and a 1-year high of $13.57.

OraSure Technologies (NASDAQ:OSUR – Get Rating) last released its quarterly results on Wednesday, February 23. The medical device supplier reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.02. The company posted revenue of $63.57 million in the quarter, versus a consensus estimate of $59.99 million. OraSure Technologies posted a negative return on equity of 5.83% and a negative net margin of 9.84%. The company’s revenue increased 1.1% year over year. In the same quarter a year earlier, the company posted EPS of $0.03. As a group, sell-side analysts expect OraSure Technologies to post -0.1 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently changed their holdings in the company. Geneos Wealth Management Inc. increased its position in shares of OraSure Technologies by 203.1% during the third quarter. Geneos Wealth Management Inc. now owns 3,880 shares of the medical device supplier worth $41,000 after acquiring an additional 2,600 shares in the last quarter. Lazard Asset Management LLC increased its position in OraSure Technologies by 72.8% during the fourth quarter. Lazard Asset Management LLC now owns 7,737 shares of the medical device supplier valued at $67,000 after buying 3,260 additional shares in the last quarter. CIBC Asset Management Inc. acquired a new stake in OraSure Technologies in the fourth quarter valued at approximately $92,000. Teacher Retirement System of Texas bought a new stake in OraSure Technologies in the third quarter worth approximately $131,000. Finally, ARGI Investment Services LLC acquired a new stake in OraSure Technologies in the third quarter worth approximately $133,000. Hedge funds and other institutional investors own 98.74% of the company’s shares.

About OraSure Technologies (Get an evaluation)

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe and worldwide. It operates in two segments, Diagnostics and Molecular Solutions. The Company’s main products include InteliSwab COVID-19 Rapid Test, InteliSwab COVID-19 pro Rapid Test, InteliSwab COVID-19 rx Rapid Test, OraQuick Rapid HIV Test, OraQuick In-Home HIV Test, Self Test OraQuick HIV, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with HIV-1 antibody screening and confirmation tests; Intercept drug screening systems; immunoassay tests and reagents; and CQFD

Featured articles



Receive daily news and reviews for OraSure Technologies – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for OraSure Technologies and related companies with MarketBeat.com’s FREE daily email newsletter.

Share.

Comments are closed.